Compared with other systemic agents for treating atopic dermatitis, dupilumab is associated with an increased risk for ...

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

PORTLAND, OR, UNITED STATES, June 18, 2025 /EINPresswire.com/ -- The global atopic dermatitis market is witnessing unprecedented growth, projected to expand from $5.3 billion in 2021 to $22.6 billion ...

Paris: Sanofi has successfully priced its offering of euro 1.5 billion of notes across 2 tranches:€750 million fixed-rate ...

Topical ruxolitinib cream shows promise as a treatment for inflammatory skin conditions, but lacks consistent data, indicating a need for further research into its use across various dermatologic ...

Ruxolitinib 0.75% cream and ruxolitinib 1.5% cream are effective and well-tolerated in children aged 2 to 11 years with atopic dermatitis.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

AbCellera Biologics' drug candidates in Phase 1 trials show promise, but financial losses and slow progress raise concerns.

Greater disease control and satisfaction as well as lower recurrence rates were associated with isotretinoin 20 mg vs 10 mg for seborrheic dermatitis.

Cells and processes that bring about the effect of immunotherapy on atopic dermatitis have been revealed. A research team led by Park Chang-wook, a dermatologist at Severance Hospital, Park Jung-won, ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...